Welcome to our dedicated page for Microbot Med SEC filings (Ticker: MBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Microbot Medical filings document formal disclosures tied to the LIBERTY Endovascular Robotic System and the company’s commercial-stage medical-device operations. Recent Form 8-K reports furnish Regulation FD press releases on U.S. market release activity, healthcare-system adoption, procedure use, medical-society occupational-protection guidelines, and publication of the ACCESS-PVI pivotal study.
The filings also record Item 8.01 other-event disclosures and capital-markets matters, including an at-the-market common stock program under a shelf registration statement. These records describe the company’s Nasdaq-listed common stock, product commercialization, clinical-evidence communications, commercial organization updates, and related exhibit filings.
Microbot Medical Inc. proposes an at-the-market offering to sell up to $39,230,691 aggregate offering price of its common stock through H.C. Wainwright & Co., acting as sales agent, under an amended sales agreement.
As of December 31, 2025, Microbot reported 67,158,044 shares outstanding; the prospectus shows an as adjusted figure of 83,851,955 shares reflecting an assumed sale of 16,693,911 shares at an illustrative price of $2.35 per share (the April 8, 2026 closing price referenced). The offering permits sales on Nasdaq or by other methods permitted as an ATM; Wainwright’s commission is 3.0% of gross proceeds. The company discloses intended use of proceeds for LIBERTY® development, regulatory and commercialization activities, potential IP acquisitions, and general corporate purposes, and notes ongoing risks related to regional hostilities in Israel that could affect operations.
Microbot Medical Inc. is activating its existing at-the-market equity program with H.C. Wainwright & Co. Under this arrangement, the company may sell shares of its common stock, par value $0.01 per share, from time to time up to an aggregate offering price of $39,230,691.
Sales can occur on the Nasdaq Capital Market, through market makers, or directly to Wainwright in negotiated transactions at prevailing market prices or prices related to them. These sales will be made under a shelf registration statement on Form S-3, using a prospectus and a new prospectus supplement filed with the SEC. The company also filed a legal opinion from its counsel on the validity of the shares.
Microbot Medical Inc. director Aileen Ptucha Stockburger received a grant of stock options covering 10,000 shares of common stock. The options have an exercise price of $2.37 per share, were granted on April 1, 2026, and are scheduled to expire on April 1, 2036.
Microbot Medical Inc. director Madden Martin J. received a grant of stock options representing 10,000 shares of common stock. The options have an exercise price of $2.37 per share, were granted on April 1, 2026, and expire on April 1, 2036.
This is a compensation-related award, not an open-market purchase or sale, and leaves the director holding 10,000 options following the transaction.
Microbot Medical Inc. director Wenderow Tal Baruch received a grant of stock options, giving the right to buy 10,000 shares of common stock. The options have an exercise price of $2.37 per share and expire on April 1, 2036. Following this grant, Baruch holds stock options covering 10,000 shares directly.
Microbot Medical Inc. director David James Wilson received a grant of stock options covering 10,000 shares of common stock. The options were awarded at an exercise price of $2.37 per share, carry no upfront cost, and were granted on April 1, 2026.
These options give him the right to buy 10,000 shares of Microbot Medical common stock at $2.37 per share until their expiration on April 1, 2036. After this grant, he holds 10,000 stock options directly, with no additional derivative positions shown in this filing.
Microbot Medical Inc. director Burell Scott R reported receiving a grant of stock options. On April 1, 2026, he was awarded options to acquire 10,000 shares of common stock at an exercise price of $2.37 per share, expiring on April 1, 2036. Following this grant, he holds stock options covering 10,000 underlying shares directly.
Microbot Medical Inc. director Laxminarain Prattipati received a grant of stock options covering 10,000 shares of common stock. The options have an exercise price of $2.37 per share, were granted on April 1, 2026, and expire on April 1, 2036.
Following this grant, Prattipati holds stock options for 10,000 shares directly. This is a compensation-related award, not an open‑market purchase or sale of Microbot Medical common stock.
Microbot Medical provides an in-depth annual update on its transition from R&D to commercialization of the FDA‑cleared LIBERTY® Endovascular Robotic Surgical System, its sole product. The company began a limited U.S. market release in November 2025 and is planning a full launch around the Society of Interventional Radiology conference in April 2026.
LIBERTY is a compact, single‑use, remotely operated robotic system aimed at peripheral endovascular procedures, with telerobotic capabilities still under evaluation. Microbot reports no revenues through December 31, 2025 and continues to incur significant operating losses while investing heavily in R&D, manufacturing scale‑up and commercial infrastructure.
The company received ISO 13485:2016 certification in 2024 to support CE Marking, and anticipates CE Mark approval for LIBERTY in the second half of 2026, enabling European sales. Operations rely on third‑party manufacturing, Israeli government grants, and a 43‑person workforce in the U.S. and Israel, while management highlights ongoing capital needs and detailed risk factors, including geopolitical risks tied to recent Middle East hostilities.
Microbot Medical Inc. filed an update highlighting real-world use of its LIBERTY Endovascular Robotic System at Emory Healthcare. Emory’s interventional radiologists successfully performed robotic peripheral endovascular procedures, including the world’s first robotic prostatic artery embolization for benign prostatic hyperplasia and robotic Y-90 radioembolization mapping for liver cancer.
The LIBERTY System is described as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, designed to enhance precision, reduce radiation exposure and physical strain, and improve procedural efficiency. Microbot began a Limited Market Release in November 2025 and plans a Full Market Release at the Society of Interventional Radiology conference in April 2026 to further drive adoption.